Antiviral RNAi

Volume 721 of the series Methods in Molecular Biology pp 339-353


Antibody-Mediated Delivery of siRNAs for Anti-HIV Therapy

  • Sang-Soo Kim
  • , Sandesh Subramanya
  • , Dan Peer
  • , Motomu Shimaoka
  • , Premlata ShankarAffiliated withDepartment of Biomedical Sciences, Center of Excellence for Infectious Diseases, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center Email author 

* Final gross prices may vary according to local VAT.

Get Access


RNA interference (RNAi) is a potent and specific gene silencing mechanism that utilizes small ­double-stranded RNA intermediates (small interfering RNAs or siRNAs) to target homologous mRNA sequences for degradation. The therapeutic potential of RNAi for HIV infection has been demonstrated in many studies. However, successful clinical application of RNAi is contingent on developing practical strategies to deliver siRNA to the desired target cells and tissues. Recently, there has been significant progress towards developing reagents that selectively deliver exogenous siRNA to immune cells that are targeted by HIV or involved in viral pathogenesis, such as T cells, macrophages, and dendritic cells. Here, we describe details of two antibody-based strategies for systemic delivery of siRNA either specifically to T cells via the CD7 receptor or to multiple immune cell types via LFA-1, present on all leukocytes.

Key words

RNA interference Small interfering RNA Targeted delivery Cationic peptide Liposome scFvCD7 Integrin LFA-1 (lymphocyte function-associated antigen-1) I-tsNPs (integrin-targeted stabilized nanoparticles) HIV